Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3356 |
|
| Actual shortage: | 218 (6%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 10 (0%) | |
| Resolved: | 3128 (93%) | |
Discontinuation Reports |
359 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 335 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
61 (25%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-CEFEPIME | 1G | POWDER FOR SOLUTION | Resolved | 2020-05-13 | 2020-05-19 | 114937 |
| APO-CEFEPIME | 2G | POWDER FOR SOLUTION | Resolved | 2024-05-24 | 2024-06-21 | 228807 |
| APO-CEFEPIME | 2G | POWDER FOR SOLUTION | Resolved | 2024-07-18 | 2024-08-16 | 233343 |
| APO-CEFEPIME | 1G | POWDER FOR SOLUTION | Resolved | 2024-09-20 | 2024-11-08 | 238245 |
| APO-CEFEPIME | 1G | POWDER FOR SOLUTION | Resolved | 2024-12-05 | 2025-02-14 | 244915 |
| APO-CEFEPIME | 1G | POWDER FOR SOLUTION | Resolved | 2024-01-19 | 2024-02-09 | 216672 |
| APO-CEFEPIME | 2G | POWDER FOR SOLUTION | Resolved | 2024-02-23 | 2024-03-01 | 220444 |
| APO-CEFEPIME | 1G | POWDER FOR SOLUTION | Resolved | 2024-05-03 | 2024-06-21 | 227082 |
| APO-CEFEPIME | 2G | POWDER FOR SOLUTION | Resolved | 2021-06-11 | 2021-08-06 | 140772 |
| APO-CEFEPIME | 2G | POWDER FOR SOLUTION | Resolved | 2021-09-17 | 2021-10-25 | 145822 |
| APO-CEFPROZIL | 500MG | TABLET | Actual shortage | 2018-09-28 | 2018-09-28 | 62607 |
| APO-CEFPROZIL | Resolved | 2018-09-28 | 2019-06-12 | 62614 | ||
| APO-CEFPROZIL | Resolved | 2018-09-28 | 2019-05-24 | 62618 | ||
| APO-CEFPROZIL | 250MG | TABLET | Resolved | 2017-03-10 | 2017-10-03 | 71 |
| APO-CEFPROZIL | 500MG | TABLET | Resolved | 2017-03-10 | 2017-10-03 | 74 |
| APO-CEFUROXIME | 500MG | TABLET | Resolved | 2017-03-17 | 2017-06-12 | 3163 |
| APO-CEFUROXIME | 250MG | TABLET | Resolved | 2018-02-05 | 2018-04-14 | 38505 |
| APO-CEFUROXIME | 500MG | TABLET | Resolved | 2018-02-13 | 2018-04-14 | 39650 |
| APO-CEFUROXIME | 250MG | TABLET | Resolved | 2023-02-02 | 2023-02-09 | 183495 |
| APO-CEFUROXIME | 250MG | TABLET | Resolved | 2021-09-17 | 2021-10-12 | 145828 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |